<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147523</url>
  </required_header>
  <id_info>
    <org_study_id>PolyzosKountouras</org_study_id>
    <nct_id>NCT01147523</nct_id>
  </id_info>
  <brief_title>Effect of Spironolactone and Vitamin E in Patients With Nonalcoholic Fatty Liver Disease</brief_title>
  <acronym>NAFLD</acronym>
  <official_title>The Effect of Spironolactone and Vitamin E Versus Vitamin E on Serum Adipocytokines Levels in Patients With Biopsy-proven Nonalcoholic Fatty Liver Disease-A Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of the study is the effect of spironolactone and vitamin E versus vitamin E
      on serum levels of adipokines 52 weeks post-treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Unlike other chronic liver diseases (e.g., hepatitis C), there are no effective treatment
      strategy for NAFLD. Currently, the management of NAFLD includes modification of underlying
      risk factors, detection of patients that have progressed to cirrhosis, management of
      cirrhosis-related morbidity and transplantation in patients with end-stage liver disease.
      Diet, exercise, bariatric surgery and pharmacologic treatment, including weight loss agents,
      insulin sensitizers, lipid-lowering agents, ursodeoxycholic acid and vitamin E have been
      investigated with some promising results.

      The renin-angiotensin-aldosterone system (RAAS) has been implicated in the pathogenesis of
      insulin resistance (IR) and nonalcoholic fatty liver disease (NAFLD). Recently, low-dose
      (25-50 mg/day) aldosterone antagonists in patients with heart failure diminish mortality,
      possibly by reducing cardiac and vascular fibrosis. Moreover, the beneficial effect of
      spironolactone in a mouse model with diet-induced diabetes and NAFLD has been reported.
      However, to our knowledge, the role of spironolactone in NAFLD patients has not been
      investigated yet.

      The primary aim of the study is the effect of spironolactone and vitamin E versus vitamin E
      on serum levels of adipokines 52 weeks post-treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum adipocytokines levels</measure>
    <time_frame>52 weeks</time_frame>
    <description>Adiponectin; visfatin; leptin; resistin; omentin; vaspin; RBP4; TNF-alpha, IL-6; IL-1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum homocysteine levels</measure>
    <time_frame>52 weeks</time_frame>
    <description>Homocysteine; vitamin B12; folate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Liver histology</measure>
    <time_frame>52 weeks</time_frame>
    <description>Repeat biopsy, if patients provide their consent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin resistance</measure>
    <time_frame>52 weeks</time_frame>
    <description>Serum insulin; serum glucose; HOMA and QUICKI indexes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hormonal profile</measure>
    <time_frame>52 weeks</time_frame>
    <description>DHEAS; testosterone; estradiol; TSH; free T4; cortisol (serum levels)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum biochemistry</measure>
    <time_frame>52 weeks</time_frame>
    <description>ALT; AST; ggt; Potassium; Sodium; urea; creatinin; cholesterol; triglycerides; HDL; LDL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reactive Oxygen Metabolites (ROMs)</measure>
    <time_frame>52 weeks</time_frame>
    <description>Serum dROMs leves</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Fatty Liver</condition>
  <condition>Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>Vitamin E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vitamin E, capsules 400 mg daily, for 52 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone/Vitamin E</intervention_name>
    <description>Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks</description>
    <arm_group_label>Vitamin E</arm_group_label>
    <other_name>Aldactone tab 25</other_name>
    <other_name>Eviol caps 100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Bright liver on ultrasound imaging and increased liver function tests for at least 6
             months before liver biopsy

          -  Biopsy-proven NAFLD (either NAFL or NASH) according to NAFLD Activity Score (NAS)

        Exclusion Criteria:

          -  Ethanol consumption more than 20 g/day

          -  Known intolerance to spironolactone or vitamin E

          -  History of liver disease (chronic viral hepatitis, autoimmune hepatitis, drug-induced
             liver disease, primary biliary cirrhosis, hemochromatosis, Wilson's disease and
             Î±1-antitrypsin deficiency)

          -  Previous exposure to hepatotoxic drugs

          -  Spironolactone or vitamin E administration within one year before screening

          -  Type I Diabetes Mellitus

          -  Pancreatitis

          -  Uncontrolled hypothyroidism or hyperthyroidism

          -  Adrenal Insufficiency

          -  Renal Failure

          -  Cancer

          -  Pregnancy

        Exclusion criteria were generally the same as those proposed for PIVENS trial design with
        two modifications: a) known intolerance to spironolactone as an exclusion criterion and b)
        the inclusion of patients with T2DM not receiving thiazolidinediones or insulin.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stergios A Polyzos, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jannis Kountouras, MD, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Efthimia Zafeiriadou, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Radiology, Ippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kalliopi Patsiaoura, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pathology, Ippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Evangelia Katsiki, MD</last_name>
    <role>Study Director</role>
    <affiliation>Department of Pathology, Ippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aristidis Slavakis, MD, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Department of Biochemistry, Ippokration Hospital, Thessaloniki, Greece</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Second Medical Clinic, Medical School, Aristotle University of Thessaloniki, Ippokration Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54642</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C. Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med. 2009 Apr;9(3):299-314. Review.</citation>
    <PMID>19355912</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C. Insulin resistance and therapy: cross-talk between phosphatidylinositol-3 kinase and mitogen-activated protein kinase pathways. Med Hypotheses. 2009 May;72(5):610. doi: 10.1016/j.mehy.2008.12.019. Epub 2009 Jan 21.</citation>
    <PMID>19162411</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos Ch. The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in non alcoholic fatty liver disease. Hippokratia. 2009 Apr;13(2):127; author reply 128.</citation>
    <PMID>19561788</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C. Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis. J Clin Gastroenterol. 2010 Mar;44(3):229-30; author reply 230-1. doi: 10.1097/MCG.0b013e3181b5ce68.</citation>
    <PMID>19770674</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Stergiopoulos C. Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: the two sides of the same coin. Med Hypotheses. 2010 Jun;74(6):1089-90. doi: 10.1016/j.mehy.2009.12.028. Epub 2010 Jan 18.</citation>
    <PMID>20080361</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C. Adiponectin as a potential therapeutic agent for nonalcoholic steatohepatitis. Hepatol Res. 2010 Apr;40(4):446-7. doi: 10.1111/j.1872-034X.2010.00632.x.</citation>
    <PMID>20394676</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010 May;12(5):365-83. doi: 10.1111/j.1463-1326.2009.01176.x. Review.</citation>
    <PMID>20415685</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature. J Clin Gastroenterol. 2011 Jan;45(1):50-4. doi: 10.1097/MCG.0b013e3181ec5c66. Review.</citation>
    <PMID>20717042</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Toulis KA, Goulis DG, Zavos C, Kountouras J. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2011 Mar;60(3):313-26. doi: 10.1016/j.metabol.2010.09.003. Epub 2010 Oct 30. Review.</citation>
    <PMID>21040935</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C. Adiponectin in non-alcoholic fatty liver disease treatment: therapeutic perspectives and unresolved dilemmas. Int J Clin Pract. 2011 Mar;65(3):373-4. doi: 10.1111/j.1742-1241.2010.02594.x.</citation>
    <PMID>21314876</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Deretzi G. The association between Helicobacter pylori infection and insulin resistance: a systematic review. Helicobacter. 2011 Apr;16(2):79-88. doi: 10.1111/j.1523-5378.2011.00822.x. Review.</citation>
    <PMID>21435084</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Deretzi G. The potentially dual-faceted nature of fetuin-A in Helicobacter pylori infection and insulin resistance. Clinics (Sao Paulo). 2011;66(5):911-2.</citation>
    <PMID>21789399</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Deretzi G. Helicobacter pylori and insulin resistance association: not just a myth, not yet a fact. Saudi J Gastroenterol. 2011 Nov-Dec;17(6):425-6. doi: 10.4103/1319-3767.87190.</citation>
    <PMID>22064347</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Deretzi G, Zavos C, Mantzoros CS. The emerging role of endocrine disruptors in pathogenesis of insulin resistance: a concept implicating nonalcoholic fatty liver disease. Curr Mol Med. 2012 Jan;12(1):68-82. Review.</citation>
    <PMID>22082482</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Deretzi G, Zavos C, Gavalas E, Katsinelos P, Mane V, Slavakis A. Serum homocysteine levels in patients with nonalcoholic fatty liver disease. Ann Hepatol. 2012 Jan-Feb;11(1):68-76.</citation>
    <PMID>22166563</PMID>
  </reference>
  <reference>
    <citation>Polyzos SA, Kountouras J, Patsiaoura K, Katsiki E, Zafeiriadou E, Zavos C, Deretzi G, Tsiaousi E, Slavakis A. Serum vitamin B12 and folate levels in patients with non-alcoholic fatty liver disease. Int J Food Sci Nutr. 2012 Sep;63(6):659-66. doi: 10.3109/09637486.2011.649249. Epub 2012 Jan 9.</citation>
    <PMID>22229957</PMID>
  </reference>
  <results_reference>
    <citation>Polyzos SA, Kountouras J, Zafeiriadou E, Patsiaoura K, Katsiki E, Deretzi G, Zavos C, Tsarouchas G, Rakitzi P, Slavakis A. Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease. J Renin Angiotensin Aldosterone Syst. 2011 Dec;12(4):498-503. doi: 10.1177/1470320311402110. Epub 2011 Mar 24.</citation>
    <PMID>21436212</PMID>
  </results_reference>
  <results_reference>
    <citation>Polyzos SA, Kountouras J, Zavos C, Deretzi G. Spironolactone revisited. J Clin Hypertens (Greenwich). 2011 Oct;13(10):783-4. doi: 10.1111/j.1751-7176.2011.00484.x. Epub 2011 Jul 18.</citation>
    <PMID>21974769</PMID>
  </results_reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>January 19, 2012</last_update_submitted>
  <last_update_submitted_qc>January 19, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>Stergios A. Polyzos</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <keyword>nonalcoholic fatty liver disease</keyword>
  <keyword>nonalcoholic steatohepatitis</keyword>
  <keyword>adipokines</keyword>
  <keyword>spironolactone</keyword>
  <keyword>vitamin E</keyword>
  <keyword>adiponectin</keyword>
  <keyword>visfatin</keyword>
  <keyword>leptin</keyword>
  <keyword>resistin</keyword>
  <keyword>TNF-alpha</keyword>
  <keyword>IL-6</keyword>
  <keyword>IL-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

